Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00839319 · ClinicalTrials.gov registry record · Phase 1
HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone
A Phase 1 study of Healthy Males, sponsored by University of Washington.
- Completed
- Registry status
- Phase 1
- Development phase
- 59
- Enrollment target
- 1
- Study location
NCT00839319: Completed Phase 1 study of Healthy Males, sponsored by University of Washington.
NCT00839319 is a Phase 1 study of Healthy Males that has completed, run by University of Washington. The registered enrollment target is 59 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00839319, a Phase 1 study of Healthy Males, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 59 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.
Conditions Studied
Interventions
- DRUG Acyline
- OTHER placebo hCG (no active ingredient)
- DRUG hCG (human chorionic gonadotropin)
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
What the finished NCT00839319 record still lists
NCT00839319 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Healthy Males appearing as the primary indexed condition, and to 3 interventions - of which Acyline is the first listed.
NCT00839319 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT00839319 about?
NCT00839319 is a clinical study titled "HOP-3 Manipulation of the Intratesticular Hormonal Milieu With Exogenous Testosterone". The purpose of this investigational study is to determine how much male hormone, testosterone, is necessary to maintain sperm production in the testis. This knowledge will be used to help in the development of a safe male hormonal contraception.
What is the current status of trial NCT00839319?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 59 participants. The study started on 2009-03. Estimated completion is 2010-11.
What conditions does trial NCT00839319 study?
This clinical trial studies the following conditions: Healthy Males.
What interventions are being tested in trial NCT00839319?
The interventions under investigation include: Acyline (DRUG), placebo hCG (no active ingredient) (OTHER), hCG (human chorionic gonadotropin) (DRUG).
Who is sponsoring clinical trial NCT00839319?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00839319 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Males
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00839319's enrollment target sits among peer trials
59 895th of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia